RPE65 and Leber congenital amaurosis: While many interventional clinical trials for IRDs have been completed or are ongoing, only one gene therapy product, voretigene neparvovec-rzyl (Luxturna), has been approved for the treatment of patients with biallelic genetic variations in the RPE65 gene, typically diagnosed as Leber congenital amaurosis (LCA) type 2 or severe early-onset retinitis pigmentosa (RP).24